Data as of Q4 2025 (Dec 31, 2025)

Vivo Capital, LLC

โ€ขCIK: 1674712โ€ขFiling: Q4 2025

**Vivo Capital, LLC** manages $1.5B across a concentrated portfolio of 47 positions. The fund exhibits significant conviction in select names, with TERN anchoring the top holding at $216.0M. Further notable allocations include CDTX ($211.3M) and PRAX ($96.9M), indicating a focused, high-conviction approach. This structure suggests an active, deep-value mandate targeting outsized returns within specific sectors.

Total AUM
$1.5B
QoQ Performance
+24.5%
Positions
47
Top 10 Concentration
60.1%
Latest Filing
Q4 2025

Top Holdings Allocation

TERN
CDTX
PRAX
COGT
TERN14.0%
CDTX13.7%
PRAX6.3%
COGT5.5%
TRVI4.1%
Avadel3.7%
CMPX3.3%
DYN3.3%

๐Ÿ“ˆ Biggest Buys

PRAX
Praxis Precision Medicines
+65.4%
6.3% of portfolio
DBVT
DBV Technologies SA
+133.4%
3.1% of portfolio
ANRO
Alto Neuroscience Inc
NEW
1.2% of portfolio
NERV
Minerva Neurosciences Inc
NEW
1.1% of portfolio
DSGN
Design Therapeutics Inc
NEW
1.0% of portfolio

๐Ÿ“‰ Biggest Sells

CDTX
Cidara Therapeutics, Inc.
-27.1%
13.7% of portfolio
SLNO
Soleno Therapeutics Inc
-60.7%
2.7% of portfolio
TERN
Terns Pharmaceuticals Inc
-22.5%
14.0% of portfolio
OLMA
Olema Pharmaceuticals Inc
-55.4%
1.1% of portfolio
COGT
Cogent Biosciences Inc
-14.0%
5.5% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

VRNA
Verona Pharma PLC
SOLD
$148.7M
โ€”
Tourmaline Bio Inc.
SOLD
$28.3M
AKRO
Akero Therapeutics Inc
SOLD
$20.6M
RZLT
Rezolute Inc
SOLD
$19.9M
CATBUSD
Astria Therapeutics Inc
SOLD
$11.3M
+2 more exited positions

Changes from Q3 2025

NEW7 new positions
โ†‘4 increased
โ†“9 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023